Durect   Report issue

For profit Phase 2 Phase 3
Founded: Cupertino California United States (1998)

Organization Overview

First Clinical Trial
2006
NCT00478179
First Marketed Drug
2021
levobupivacaine (chirocaine)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Durect | DURECT

Active Ingredients

Marketed Drugs (1)

levobupivacaine (chirocaine) (2021)

Drugs in Phase 3 Trials (2)

levobupivacaine (chirocaine) (8 trials)

methylphenidate (ritalin) (2 trials)

Drugs in Phase 2 Trials (3)

bupivacaine (Exparel) (1 trial)

larsucosterol (2 trials)

sulfated oxysterol (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 3)

Back Pain (Phase 2)

Cholangitis (Phase 2)

Cholangitis, Sclerosing (Phase 2)

Chronic Pain (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis, Alcoholic (Phase 2)

Hernia (Phase 2)

Low Back Pain (Phase 2)

Neuralgia (Phase 2)

Neuralgia, Postherpetic (Phase 2)

Pain, Postoperative (Phase 3)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 5